Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 19, 2017
Pharmacy Choice - News - Pharmaceutical Development - September 19, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/20/17 - Researchers' Work from Bioinformatics Center Focuses on Life Science Research (THPdb: Database of FDA-approved peptide and protein therapeutics)
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Current study results on Life Science Research have been published. According to news reporting originating from Chandigarh, India, by NewsRx correspondents, research stated, "THPdb is a manually curated repository of Food and Drug Administration approved therapeutic peptides
8/19/17 - AstraZeneca`s Lynparza gets additional US approval for ovarian cancer [Tehran Times (Iran)]
AstraZeneca and MSD have announced that the US Food and Drug Administration has granted approval for the PARP inhibitor, Lynparza. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, AstraZeneca, said: Physicians have almost three years of clinical experience with Lynparza on the market and we are now pleas
8/19/17 - Cancer Research UK and Newcastle University extend drug discovery partnership with Astex [Syrian Arab News Agency]
Cancer Research UK and Newcastle University have extended their strategic drug discovery alliance with Astex Pharmaceuticals for three years. The scientists at the Cancer Research UK Drug Discovery Programme at the Northern Institute for Cancer Research, Newcastle University, will work together to discover and develop new cancer drugs and associate
8/19/17 - FDA grants two orphan drug designations for HCC [Sudan Tribune]
The U.S. Food and Drugs Administration has granted two orphan drug designations for T cell therapy products for the treatment of hepatocellular carcinoma. The FDA Orphan drug designations are granted to drugs and biologics intended for rare diseases that affect fewer than 200,000 people in the U.S, and provides incentives that may include tax credi
8/19/17 - Fruit Street Becomes the First Digital Health Company to Deliver the CDC's Diabetes Prevention Program via Live Group Telehealth Classes
The digital health and telemedicine company Fruit Street Health has announced that it is the first organization with pending recognition status from the Centers for Disease Control and Prevention to deliver the CDC' s National Diabetes Prevention Program via group telehealth classes and live video conferencing. The DPP resulted from clinical work..
8/19/17 - JUNO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Juno Therapeutics, Inc. - JUNO
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick& Foti, LLC, announces that KSF has commenced an investigation into Juno Therapeutics, Inc.. In November 2016, it was revealed that the FDA had suspended the JCAR015 trial and on March 1, 2017, the Company announced it was ending the drug tria
8/19/17 - New treatment for deadly blood cancers expected to be approved soon [St. Louis Post-Dispatch]
Aug. 19 Cancer doctors in St. Louis are ready to use a new therapy using a patient's own blood to fight their disease. At least 16 of the 20 people who have received CAR-T therapy for leukemia or lymphoma through clinical trials at Washington University's Siteman Cancer Center have seen their cancers disappear after treatment. Armin Ghobadi, an a
8/19/17 - Pfizer wins approval for blood cancer drug Besponsa [Sudan Tribune]
Pfizer today won FDA approval for a new targeted drug for the treatment of relapsed or refractory acute lymphoblastic leukemia. The FDA said nearly 6,000 people in the U.S. will be diagnosed with ALL this year and about 1,440 will die from the disease. A Pfizer spokesperson said in an email, that based on the typical duration of treatment, the tota
8/19/17 - Sedgwick Joins West Cancer Center in Mission to Eradicate Cancer
Sedgwick, the leading global provider of technology-enabled claims and productivity management solutions, has partnered with West Cancer Center in the fight against cancer by committing to serve as presenting sponsor of its signature fundraising eventWest Fight On: Cycle. West Cancer Center provides the most comprehensive cancer treatment...
8/18/17 - $70.3 Billion Biologics Outsourcing Markets, 2025
These organizations bridge the gap between demand and supply and ensure the drug discovery process gets much faster and convenient thus bringing life saving drugs to the market to reach the needy patients. Key Topics Covered: 1 Biologics Outsourcing Global Market 1.1 Introduction 1.2 Landscape of Biologics Market 1.3 Biologics Global Market 1.4 Chi
8/18/17 - Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM
Release date- 17082017- Montreal, Quebec, CANADA- Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of CaPre for the treatment of severe hypertriglyceridemia, announced that the following individuals were elected as directors of Acasti Pharma Inc. at its Annual and Special Meeting of...
8/18/17 - Achieve Life Sciences initiates cytisine clinical development programme [T-break Tech (Middle East)]
Cytisine is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 15 years. It is estimated that over 20 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, phase 3 clinical trials in Europe and New Zealand.
8/18/17 - ANGIOSOMA, INC. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
AngioSoma is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease. Nine Months Ended June 30, 2017 Compared to the Period from Inception through June 30, 2016. We recognized general and...
8/18/17 - Ascendis Pharma A/S Reports Second Quarter 2017 Financial Results
Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced financial results for the quarter ended June 30, 2017. Continued enrollment of subjects in the phase 3 heiGHt Trial for TransCon Growth Hormone in pediatric growth hormone..
8/18/17 - AstraZeneca and Merck & Co., Inc. - LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer
Release date- 17082017- KENILWORTH, N.J.- AstraZeneca and Merck& Co., Inc., known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has granted approval for the PARP inhibitor, LYNPARZA. Sean Bohen, executive vice president, global medicines development and chief medical officer of AstraZeneca,
8/18/17 - AstraZeneca and Merck & Co., Inc. - LYNPARZA receives additional FDA approval in the US for ovarian cancer
Release date- 17082017- AstraZeneca and Merck& Co., Inc., today announced that the US Food and Drug Administration has granted approval for the PARP inhibitor, LYNPARZA, as follows. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, AstraZeneca said:' Physicians have almost three years of clinical experien
8/18/17 - Bayer Healthcare Pharmaceuticals; Withdrawal of Approval of a New Drug Application for BAYCOL (cerivastatin sodium) Tablets, 0.05 Milligrams, 0.1...
FOR FURTHER INFORMATION CONTACT: Kristiana Brugger, Office of Regulatory Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6262, Silver Spring, MD 20993, 301-796-3600.. FDA approved NDA 020740 on June 26, 1997, as safe and effective as an adjunct to diet for the reduction of eleva
8/18/17 - Biologics Outsourcing Markets, 2025 - Pharma Companies Restricting Their Global Presence, Reducing Manpower, Lack of Facilities for Discovery and Manufacturing of Biologics
The "Biologics Outsourcing Global Market- Forecast to 2025" report has been added to Research and Markets' offering. The biologics outsourcing global market is expected to grow at double digit CAGR to reach $70.3 billion by 2025. These organizations bridge the gap between demand and supply and ensure the drug discovery process gets much faster and
8/18/17 - Biopharmaceutical CMO & CRO Market (2017-2025) - Analysis By Source, Service Type, Product & Segment - Research and Markets
The "Biopharmaceutical CMO& CRO Market Analysis By Source, By Service Type, By Product, And Segment Forecasts, 2014- 2025" report has been added to Research and Markets' offering. The global biopharmaceutical CMO& CRO market is expected to reach USD 37.8 billion by 2025, according to this new report. Healthy outlook of biopharmaceuticals and conseq
8/18/17 - Biopharmaceutical CMO & CRO Market to Value $37.8 Billion by 2025: Regional Estimates & Trend Analysis, by Service, Source, & Product
The " Biopharmaceutical CMO& CRO Market, 2014- 2025" report has been added to Research and Markets' offering. Boehringer Ingelheim GmbH LONZA Inno Biologics Sdn Bhd Rentschler Biotechnologie GmbH JRS PHARMA CELONIC AG BIOMEVA GmbH ProBioGen FUJIFILM Diosynth Biotechnologies U.S.A., Inc. TOYOBO CO., LTD. Samsung BioLogics Patheon DPx CMC Biologics B
8/18/17 - Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) at ESC Congress 2017
PRINCETON, N.J.& NEW YORK Bristol-Myers Squibb Company and Pfizer Inc. today announced that 15 abstracts have been accepted for presentation at the ESC Congress 2017, organized by the European Society of Cardiology, on August 26-30 in Barcelona, Spain. We are proud to share both clinical trial results and real-world data analyses that contin
8/18/17 - Cancer Genetics pays $12M for Australian CRO vivoPharm [Arab Times (Kuwait)]
U.S. oncology specialist Cancer Genetics will pay $12 million to buy out Australian contract research organization vivoPharm as it looks to bolster its offerings. Cancer Genetics says the deal will boost its position as a premier leader for oncology discovery, in vivo and in vitro drug development and early phase clinical trial testing for biotechn
8/18/17 - Cancer Research UK and Newcastle University extend successful multi-project drug discovery alliance with Astex Pharmaceuticals [Syrian Arab News Agency]
Cancer Research UK* and Newcastle University announce a three year extension to their major strategic drug discovery alliance with Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics. The researchers at the Cancer Research UK Drug Discovery Programme at the Northern...
8/18/17 - Cancer Research UK, Newcastle University Extend Successful Multi-Project Drug Discovery Alliance With Astex Pharmaceuticals
Cancer Research UK* and Newcastle University announce a three year extension to their major strategic drug discovery alliance with Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics. In return, Cancer Research UK and Newcastle University are eligible to receive milestone a
8/18/17 - Catawba Research Brings Fresh Perspective to Clinical Trial Management [Syrian Arab News Agency]
-Over the last three years, Catawba Research has entered the pharmaceutical space to much industry attention. The North Carolina- based, multimillion dollar company has doubled its revenue and the number of studies initiated every six months. Drawing on more than 25 years of experience in executing clinical trials for global pharmaceutical companie
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415